marijuana stocks news

Cara Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015

SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, March 26, 2015, at 4:30 p.m. ET to report fourth quarter and full year 2014 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 1527720. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

View photo

.

Contact:
Investor Contact
Jesse Baumgartner
Stern Investor Relations
212-362-1200
jesse@sternir.com
Media Contact
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Incase you Missed it $SRNA Closes Financing Last Week

Surna Closes $1.325 Million Financing; Company Pursuing Sector Technology Leadership, Market Share…

Cara Therapeutics, Inc. (CARA) Announces Approval of KORSUVA® IV Injection Syringe in Japan

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for…

Tilray Brands (TLRY) Launches Pub Ice: a Refreshing Twist on ‘Cheap Fun

10 Barrel Brewing Launches Pub Ice: a Refreshing Twist on ‘Cheap Fun’…

Canopy Growth Corporation (CGC) Closing of Plan of Arrangement Involving RIV Capital

Canopy Growth Announces Closing of Plan of Arrangement Involving RIV Capital  …